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The Place of FDG PeT/CT in Renal 
Cell Carcinoma: value and Limitations
Yiyan Liu*
Nuclear Medicine Service, Department of Radiology, New Jersey Medical School, Rutgers University, Newark, NJ, USA
Unlike for most other malignancies, application of FDG PET/CT is limited for renal cell 
carcinoma (RCC), mainly due to physiological excretion of 18F-fluoro-2-deoxy-2-d-
glucose (FDG) from the kidneys, which decreases contrast between renal lesions and 
normal tissue, and may obscure or mask the lesions of the kidneys. Published clinical 
observations were discordant regarding the role of FDG PET/CT in diagnosing and 
staging RCC, and FDG PET/CT is not recommended for this purpose based on current 
national and international guidelines. However, quantitative FDG PET/CT imaging may 
facilitate the prediction of the degree of tumor differentiation and allows for prognosis 
of the disease. FDG PET/CT has potency as an imaging biomarker to provide useful 
information about patient’s survival. FDG PET/CT can be effectively used for postoper-
ative surveillance and restaging with high sensitivity, specificity, and accuracy, as early 
diagnosis of recurrent/metastatic disease can drastically affect therapeutic decision and 
alter outcome of patients. FDG uptake is helpful for differentiating benign or bland emboli 
from tumor thrombosis in RCC patients. FDG PET/CT also has higher sensitivity and 
accuracy when compared with bone scan to detect RCC metastasis to the bone. FDG 
PET/CT can play a strong clinical role in the management of recurrent and metastatic 
RCC. In monitoring the efficacy of new target therapy such as tyrosine kinase inhibitors 
(TKIs) treatment for advanced RCC, FDG PET/CT has been increasingly used to assess 
the therapeutic efficacy, and change in FDG uptake is a strong indicator of biological 
response to TKI.
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iNTRODUCTiON
Renal cell carcinoma (RCC) is the most common solid tumor of the kidneys, accounting for 3% of all 
malignancies and representing the seventh leading cause of cancer. The most common histological 
subtype of RCC is clear cell RCC, followed by papillary carcinoma. Standard imaging evaluation 
for the characterization of primary renal tumor includes ultrasound, CT, and MRI. Cross-sectional 
imaging, especially contrast CT, is a primary imaging modality for tumor detection and diagnosis, 
and its increasing use has led to an increased diagnosis of RCC. Surgical resection through either 
partial or radical nephrectomy remains the mainstay of treatment for the localized disease.
Positron emission tomography (PET) has emerged as one of the most important imaging modality 
in staging, restaging, detecting recurrence and/or metastasis, and monitoring therapeutic response 
in most malignant diseases (1, 2). In PET, a trace amount of a radioactive compound is adminis-
tered, and the resultant images are obtained from three-dimensional spatial reconstructions. The 
intensity of the imaging signal is proportional to the amount of tracer and, therefore, is potentially 
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semiquantitative (3). Whereas conventional imaging techniques 
can provide information on anatomic abnormalities, PET imag-
ing relies on both molecular biology and in  vivo imaging to 
provide information about the preceding changes in metabolism 
and function, including glucose metabolism, cell proliferation, 
cell membrane metabolism, or receptor expression. Furthermore, 
integrated PET/CT units allow correct co-registration and fused 
imaging of anatomical and functional data. The integration of 
CT imaging with PET has been demonstrated to significantly 
decrease false positive results and improve accuracy of the PET 
study (4–6).
18F-fluoro-2-deoxy-2-d-glucose (FDG), a non-physiological 
radiotracer with a chemical structure similar to that of naturally 
occurring glucose, is most commonly used in PET imaging. FDG 
enters cells through the same membrane glucose transporter 
proteins utilized by glucose, which are commonly overexpressed 
in cancer cells (7, 8). FDG imaging relies upon Warburg’s obser-
vation that increased glycolysis generated adenosine triphosphate 
is required to meet the metabolic demands of rapidly dividing 
tumor cells. Membrane glucose transporters, mainly GLUT-1, 
actively transport FDG into the cell, where hexokinase then 
converts it into FDG-6-phosphate. As FDG-6-phosphate is not 
a substrate for further steps in glycolysis, it is trapped in the cell 
and accumulates correspondingly to the cell’s glucose metabolic 
activity. FDG accumulation rate is semiquantitatively measured 
by the standardized uptake value (SUV). Malignant cells exhibit 
increased FDG accumulation due to increased membrane trans-
porters, increased intracellular hexokinase, and low glucose-
6-phosphatase (8).
Unlike for most other malignancies, application of FDG PET/
CT is limited for RCC, mainly due to physiological excretion of 
FDG from the kidneys, which decreases contrast between renal 
lesions and normal tissue, and may obscure or mask the lesions 
of the kidneys. However, published clinical observations were 
discordant. In the era of PET/CT in oncology, clarification and 
validation of FDG PET/CT for RCC is of great significance for 
urologists, oncologists, and radiologists. This review presents the 
studies regarding the FDG PET/CT for RCC. The role of FDG 
PET/CT is discussed based on the critical, non-structured review 
of the literature.
FDG PeT/CT FOR PRiMARY RCC
Many early clinical observations showed unfavorable results 
about the role of FDG PET/CT for detection and characterization 
of lesions of the kidney, with pooled sensitivity of 50–60% (9). 
Even forced diuresis coupled with parenteral hydration could not 
improve the sensitivity (10). In Miyakita’s study (11), 19 consecu-
tive patients with RCC were imaged using FDG PET preopera-
tively, the results of which were then compared with the histology 
obtained after radical surgery. Increased FDG uptake was found in 
only in 6 out of the 19 patients (31.5%) while immunohistochem-
istry of GLUT-1 in RCC produced varying results; there was no 
correlation of GLUT-1 immunoreactivity and FDG PET positiv-
ity. Aide et al. prospectively compared the efficiency of FDG PET 
with diagnostic CT in the characterization and primary staging 
of 35 suspicious renal masses (12). A high rate of false negative 
results was reported with FDG PET, leading to 47% sensitivity, 
80% specificity, and 51% accuracy; all lower than those of CT. The 
author concluded that, in the characterization of renal masses, 
FDG PET imaging does not offer any additional advantages com-
pared with CT. In another retrospective study of 66 patients with 
known RCC by Kang et al. (13), the accuracies of FDG PET and 
conventional imaging modalities were also compared. FDG PET 
exhibited a sensitivity of 60% and specificity of 100% for primary 
RCC tumors, while abdominal CT demonstrated 91.7% sensitiv-
ity and 100% specificity. Ozulker et al. evaluated the efficacy of 
FDG PET/CT in the detection of RCC in patients with indeter-
minate renal masses detected by conventional imaging from 18 
patients (14). All patients underwent nephrectomy or surgical 
resection of the renal mass, and the final diagnoses were based on 
histopathology. Fifteen patients had RCC, and three renal tumors 
were benign. FDG PET/CT accurately detected seven malignant 
lesions and false negative results in eight patients. FDG PET/
CT yielded true negatives in two cases of renal cortical cyst and 
false positive in one case with oncocytoma. For primary RCC 
tumors, PET showed 46.6% sensitivity, 66.6% specificity, and 50% 
accuracy. The median size of visualized tumors was greater than 
that of non-visualized tumors, and the average Fuhrman grade 
of the patients with FDG-positive malignant lesions were higher 
than that of the patients with FDG-negative lesions. There was no 
significant change in average and maximum SUVs between early 
and delayed imaging for malignant tumors.
However, some clinical observations demonstrated favorable 
results regarding the role FDG PET/CT in RCC and showed high 
FDG avidity in the majority of RCC lesions. In a study by Kumar 
et  al. (15), FDG PET was performed in 28 solid renal masses 
visualized by CT/MRI. Of the lesions, FDG PET was accurately 
able to depict 23 out of 27 (85%) malignant renal masses. Of 
the 10 primary renal tumors (9 malignant, 1 benign), FDG PET 
yielded 8 out of 9 true positive results (89%), 1 true negative, and 
1 false negative. In addition to characterization of the lesions, 
FDG PET also contributed to primary staging, altering manage-
ment in 3 out of 10 patients (30%). Of metastatic renal tumors, 
FDG PET was positive in 15 out of 18 (83%). There was no 
significant difference in SUVs between primary and metastatic 
renal masses. Nakhoda et  al. evaluated the sensitivity of FDG 
PET/CT to detect different renal lesions (16). Fifteen out of 18 
RCC were detectable by PET, whereas all renal lymphomas and 
metastases were detectable. None of the metabolic parameters 
were statistically significant between RCC and renal lymphoma. 
However, all metabolic parameters were statistically and sig-
nificantly greater for renal metastases compared with RCC and 
renal lymphoma, and for clear cell RCC compared with papillary 
RCC. In addition to a sensitivity of 88% for detection of solid 
malignant renal lesions in patients with known renal malignancy, 
FDG PET/CT also reveals differences in metabolic activity based 
on histopathological type.
Recently, Takahashi et al. retrospectively analyzed FDG PET/
CT findings in 98 lesions from 93 patients who had partial or 
radical nephrectomy after imaging (17). The SUVs of high-grade 
clear cell RCC were significantly higher when compared with that 
of the control benign lesions and low-grade tumors. An optimal 
SUV cutoff value of 3.0 had 89% sensitivity and 87% specificity 
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in differentiating between high-grade and low-grade clear cell 
RCCs. Multiple regression analysis demonstrated that a high-
grade clear cell RCC was the most significant predictor of SUV.
Overall, the results were heterogeneous. Although FDG 
PET/CT may be helpful in the characterization and detection 
of primary renal tumors, it has low negative predictive value. In 
addition, it seems that FDG PET/CT does not have significant 
advantage in diagnosis and staging of RCC compared with the 
diagnostic CT.
PReDiCTive ROLe OF FDG  
PeT/CT iN PROGNOSiS
Metabolic quantitation by SUV measurement on FDG PET/CT 
may play a role in the evaluation of biological behavior of lesion 
and prediction of patient’s prognosis. Namura et al. evaluated the 
impact of the maximum SUV (SUVmax) from FDG PET/CT on 
survival in 26 patients with advanced RCC (18). High SUVmax in 
patients with RCC correlated with poor prognosis, as there was a 
statistically significant difference in the survival between patients 
with SUVmax equal or greater than the mean of SUVmax, 8.8 and 
patients with SUVmax less than 8.8. The authors revealed that the 
SUVmax might have a role as a novel biomarker in prognosticating 
the survival time of patients with advanced RCC by multivari-
ate analyses with standard risk factors or risk classifications. In 
another study by Ferda et al. (19), 60 RCC patients had follow-ups 
for development of the disease 12 months after FDG PET/CT. The 
highest FDG accumulation was seen in the tumor of the highest 
grade, and the highest mortality was found for tumors exceeding 
SUVmax of 10. Lee et  al. investigated the relationship between 
the SUVmax of primary RCC with and without metastatic lesions 
in 23 patients (20). The median SUVmax of primary RCC of the 
16 patients without metastasis was 2.6 (range of 1.1–5.6) while 
that of the patients with metastasis was 5.0 (range of 2.9–7.6). 
The SUVmax of the primary RCC with metastasis (5.3 ± 1.7) was 
significantly higher than those without metastasis (2.9 ±  1.0). 
Thus, one of the roles of FDG PET/CT in the initial evaluation 
of a patient with RCC may be in predicting extrarenal disease, as 
patients who have primary RCC with high SUVmax are suggested 
to have a likelihood of metastasis.
Based on the limited data, quantitative FDG PET/CT imaging 
may facilitate the prediction of the degree of tumor differentiation 
and allow for prognosis of the disease. FDG PET/CT may be an 
effective imaging biomarker to provide useful information about 
patient’s survival. However, more studies are needed to justify 
these preliminary findings.
FDG PeT/CT FOR ReSTAGiNG RCC
Metastatic RCC is one of the most lethal urologic cancers. Up to 
one-third of patients with newly diagnosed RCC have metastatic 
diseases (21). Even after nephrectomy of a locally confined 
disease, more than 30% of the patients develop metastases, most 
commonly to the lung, bone, skin, liver, and brain (21). Effective 
staging of RCC, therefore, is crucial for the management of 
patients.
Although the role of FDG PET/CT in diagnosing RCC is con-
flicting, it has been more effective in the detection of metastatic 
disease, thus affecting therapeutic decisions. Obviously, size of 
the lesions has been shown to be a significant factor affecting 
sensitivity of PET/CT. Majhail et al. evaluated the performance 
of FDG PET in detecting metastatic lesions in 24 patients with 
histologically proven RCC and suspected distant metastases 
based on conventional anatomic imaging (22). Histologically 
documented distant metastases were present in 33 sites. Overall 
sensitivity, specificity, and positive predictive value of FDG PET 
for the detection of distant metastases from RCC was 63.6% (21 
out of 33), 100% (3 out of 3), and 100% (21 out of 21), respectively. 
The mean size of distant metastases in patients with true positive 
FDG PET was 2.2 cm (95% CI, 1.7–2.6 cm) compared with 1.0 cm 
in patients with false negative FDG PET.
18F-fluoro-2-deoxy-2-d-glucose (FDG) PET seems useful for 
postoperative surveillance in patients with RCC. It can detect 
recurrence in the surgical site. Nakatani et al. evaluated the surveil-
lance role of FDG PET in 23 postoperative patients with RCC (23). 
Histological final diagnosis of at least 6 months clinical follow-up 
was used to confirm diagnostic accuracy of visually interpreted 
PET. FDG PET was demonstrated to have 81% sensitivity, 71% 
specificity, and 79% diagnostic accuracy. PET was able to accurately 
detect local recurrence and metastases to the peritoneum, bone, 
muscle, and adrenal gland in all cases. In six cases (21%), addi-
tional information was obtained from scans, ultimately affecting 
the course of therapeutic management in three cases (11%). The 
cumulative survival rate over 5 years in the PET-positive was 46%, 
whereas that of the PET-negative group was 83%. Kumar et al. 
assessed 103 FDG PET/CT scans of 63 patients with suspected 
recurrent RCC after nephrectomy, confirmed with histological 
examination and/or clinical follow-up and conventional imaging 
modalities (24). The results of the 103 FDG PET/CT scans were 
63 true positive studies, 30 true negative studies, 7 false negative 
studies, and 3 false positive studies. 109 lesions were detected by 
FDG PET/CT in the 63 true positive scans. FDG PET/CT was 
demonstrated to have 90% sensitivity, 91% specificity, and 90% 
accuracy in the study. Bertagna et al. retrospectively evaluated 68 
patients with renal carcinoma who had postoperative FDG PET/
CT following partial or radical nephrectomy (25). FDG PET/
CT was reported to have 82% sensitivity, 100% specificity, 100% 
positive predictive value, 66.7% negative predictive value, and 
86.6% accuracy. In another study reported by Fuccio et al., the 
usefulness of FDG PET/CT was assessed in the restaging of 69 
RCC patients with clinical or radiological suspicion of metastases 
after nephrectomy (26). Validation of FDG PET/CT results was 
established by biopsy, other imaging modalities, and/or clinical 
and radiological follow-up of 12 months. Forty patients had true 
positive, 2 patients false positive, 23 patients true negative, and 4 
patients false negative. Sensitivity, specificity, accuracy, positive 
predictive value, and negative predictive value were 90, 92, 91, 95, 
and 85%, respectively. On a lesion basis, FDG PET/CT detected 
114 areas of abnormal uptake in 42 positive patients of which 112 
resulted to be true positive.
In another large series study, Win and Aparici retrospec-
tively reviewed the FDG PET/CT studies in 315 RCC patients 
with biopsy results (27). FDG PET/CT studies exhibited 100% 
FiGURe 1 | Demonstration of primary RCC and tumor thrombosis on 
FDG PeT/CT. A 53-year-old man had a large left renal mass seen on the CT. 
FDG PET/CT showed increased, heterogeneous uptake of the mass in the 
left kidney. There was also tumor thrombosis in the renal vein, evidenced by 
FDG avid intraluminal lesion.
FiGURe 2 | Demonstration of RCC recurrence on FDG PeT/CT. 
A 66-year-old woman had right partial nephrectomy for RCC. Two years later, 
a diagnostic CT showed a new mass in the anterior midpole of the right 
kidney, which was FDG avid on PET imaging. Subsequent nephrectomy 
confirmed recurrence of RCC.
FiGURe 3 | Demonstration of RCC recurrence on FDG PeT/CT. 
A 68-year-old man had right radical nephrectomy for RCC. FDG PET/CT was 
obtained for surveillance 5 years later, which showed a 2.0 cm density with 
moderate uptake in the surgical bed and was suspicious for recurrence. 
Surgical pathology revealed recurrent malignancy.
4
Liu FDG PET/CT in Renal Cell Carcinoma
Frontiers in Oncology | www.frontiersin.org September 2016 | Volume 6 | Article 201
sensitivity and 100% specificity in detecting all metastatic lesions 
of RCC, the smallest of which detected was a 7 mm lymph node. 
Therefore, the authors recommended the use of FDG PET/CT in 
routine standard protocols for RCC.
18F-fluoro-2-deoxy-2-d-glucose (FDG) PET/CT is a valuable 
tool both in guiding management and treatment in patients with 
RCC, as well as in predicting survival and progression. A more 
recent study confirmed the clinical role of FDG PET/CT in the 
restaging of RCC in a large group of patients (28). For recurrent 
and/or metastatic lesions in 104 patients, FDG PET/CT dem-
onstrated sensitivity and specificity of 74 and 80%, respectively. 
FDG PET/CT findings affected management therapies in 45/104 
cases (43%). In looking at overall survival (OS), positive FDG 
PET/CT associated with lower cumulative survival rates cover 
a 5-year period compared with that of negative FDG PET/CT. 
Likewise, a positive FDG PET/CT was associated with a lower 
3-year progression-free survival (PFS) rate and was associated 
with high risk of progression, alone or in combination with 
disease stage or nuclear grading.
In patients with underlying primary malignancy, there is a 
high incidence of thrombosis, which can develop from venous 
thromboembolism (VTE) or more rarely, tumor thrombus. VTE 
is a common occurrence in cancer, managed with anticoagulant 
therapy, while tumor thrombosis requires aggressive multimo-
dality therapeutics. Tumor thrombosis most commonly develops 
in solid tumors, such as RCC and hepatocellular carcinoma, 
adjacent to large veins as an extension of the malignancy and/or 
tumor infiltration (29). Sharma et al. conducted a retrospective 
review of FDG PET/CT scans in patients who had FDG-avid 
thrombosis (30). FDG PET/CT results were confirmed with 
clinical follow-up, structural imaging, and histopathology when 
available. On the basis of structural imaging and clinical follow-
up, 10 patients had benign and 14 patients had tumor thrombosis. 
The most common site of thrombosis was the inferior vena cava. 
The mean SUVmax was 3.2 in the benign thrombosis group and 
6.0 in the tumor thrombosis group. The difference in SUVmax was 
significant. In Ravina’s series (31), out of 21 tumor thrombosis 
cases incidentally detected by FDG PET/CT, 6 were from RCCs. 
Ferda et al. also reported that FDG PET/CT successfully detected 
all 7 cases with tumor invasion into the inferior vena cava of 60 
patients with RCC (19). The results showed that SUV and the 
pattern of FDG uptake are helpful for differentiating benign or 
bland emboli from tumor thrombosis in RCC patients, which is 
essential for management of patients (Figure 1).
Bone lesions associated with RCC are typically osteolytic. 
Traditional bone scintigraphy with Tc-99m methylene diphos-
phonate has limited sensitivity compared with FDG PET/CT, 
which has a higher sensitivity and a better accuracy in detecting 
bone metastases in patients with RCC. Wu et al. compared FDG 
PET with bone scan in 18 patients with biopsy-proven RCC 
and suspected bone metastases confirmed by histopathology or 
clinical follow-up of at least 1 year and conventional imaging or 
FDG PET/bone scans (32). Fifty-two bone lesions, 40 metastatic, 
and 12 benign, were found on either FDG-PET or bone scan. 
FDG PET accurately diagnosed all 40 metastatic and 12 benign 
bone lesions. In comparison, only 31 metastatic bone lesions were 
accurately detected by bone scan. FDG PET had 100% diagnostic 
sensitivity and 100% accuracy while that of bone scan were 77.5 
and 59.6%, respectively.
18F-fluoro-2-deoxy-2-d-glucose (FDG) PET/CT can provide 
useful information and has a strong clinical role in the man-
agement of recurrent and metastatic RCC (Figures  2–4). In a 
58-patient series reported by Rodriguez Martinez de Llano et al. 
(33), FDG PET/CT had the clinical impact in 25 cases (43%) and 
no impact in only 10 studies (17.2%). In more recently reported 
FiGURe 4 | Demonstration of metastatic lymph node on FDG PeT/CT. 
A 57-year-old man had the left nephrectomy for RCC 5 years ago. 
A restaging FDG PET/CT showed a 1.5 cm left para-aortic node with 
moderate uptake. Subsequent node dissection confirmed metastasis.
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large series by Alongi et  al. (28), FDG PET/CT findings influ-
enced therapeutic management in 45/104 cases (43%), treatment 
was switched from palliative to salvage in 12 patients, and new 
chemotherapy or immunotherapy was initiated in 24 patients.
Compared to conventional imaging modalities, FDG PET/
CT has the advantage in detection of early metastatic disease and 
identification of musculoskeletal metastases, which are difficult to 
assess on CT and MRI. Bertagna et al. reported that histologically 
confirmed bone metastases were revealed at FDG PET/CT in the 
presence of negative diagnostic CT in 3 out of 27 cases (25). Park 
et al. compared FDG PET/CT to conventional imaging modalities 
for restaging 63 patients with RCC who have a high risk of local 
recurrence or distant metastasis (34). FDG PET/CT accurately 
classified the presence of a recurrence or metastasis in 56 (89%) 
patients. FDG PET/CT had 89.5% sensitivity, 83.3% specificity, 
77.3% positive predictive value, 92.6% negative predictive value, 
and 85.7% accuracy in detecting recurrence or metastasis, which 
were similar to the results with conventional methods. Since 
FDG PET/CT is versatile and examines all organ systems with 
high accuracy in one procedure, and with no need for contrast 
agents, it might replace conventional methods for restaging RCC. 
Additionally, FDG PET/CT has a unique value in the prediction 
of survival and risk of progression in patients with recurrent or 
metastatic RCC (28).
However, FDG is not specific for malignant neoplasm. 
Increased uptake can be seen in many benign tumors and non-
neoplastic processes. On FDG PET/CT for RCC, the false positive 
results are often due to concomitant inflammatory/infectious 
disease (9, 28), postoperative scar (26), postradiation inflamma-
tion, etc. The most common reason of a false negative FDG PET/
CT finding is the small size of lesion and limited spatial resolution 
of PET scanner (26, 28). In RCC, another potential source of false 
negative result may be due to close proximity of the lesion to the 
urinary tract where there is physiologic urine activity (26).
FDG PeT/CT FOR MONiTORiNG 
THeRAPeUTiC ReSPONSe TO 
TYROSiNe KiNASe iNHiBiTOR
Adjuvant therapy remains a poor treatment alternative for 
advanced RCC. RCC is resistant to both conventional cytotoxic 
chemotherapy and radiation therapy, which carry a significant 
toxicity burden. However, a variety of targeted therapies including 
tyrosine kinase inhibitors (TKIs) have showed promising efficacy 
in advanced or metastatic RCC, with satisfactory results on PFS 
and quality of life (35, 36). TKIs, such as sunitinib and sorafenib, 
are antiangiogenic and can effectively inhibit tumor proliferation.
Although tumor size measurements with the response evalua-
tion criteria in solid tumors (RECIST) criteria have been used for 
monitoring response to chemotherapy, there is often little change 
in size of the lesions, and some metastases even increase in size 
while the drug is prolonging survival (37). In the recent years, 
FDG PET/CT has been increasingly used to assess the therapeutic 
efficacy of TKIs in patients with metastatic RCC. According to 
Caldarella’s systematic review of seven published studies, a 
good correlation was found between partial metabolic response 
and PFS and/or OS, with the highest survival rates in patients 
showing the greatest post-therapeutic reduction in SUVmax (38). 
In contrary, increase on FDG uptake was associated with lower 
OS (39). Pooled studies showed that FDG PET/CT had a high 
predictive value in the evaluation of response to SKI treatment in 
both skeletal and soft tissue lesions of metastatic RCC although 
there was heterogeneity of available data (38).
Some studies compared the values of FDG PET/CT and 
RECIST in predicting PFS and OS of patients treated with SKIs 
for metastatic RCC. Lyrdal et al. reported that FDG PET/CT was 
more useful than RECIST criteria, especially for the evaluation 
of skeletal lesions (40), as RECIST is limited to soft tissue lesions.
Kakizoe et al. reported that the decreased ratio of FDG accu-
mulation of RCC lesions, as assessed 1 month following initiation 
of TKI treatment by FDG PET/CT, was not influenced by the site 
of RCC metastasis (41). The study suggests that TKIs can be used 
in the treatment of advanced RCC regardless of the metastatic 
site, and that FDG PET/CT is a useful method of surveillance to 
monitor therapeutic response in all lesions.
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CONCLUSiON
Although the usefulness of FDG PET/CT in primary RCC 
remains unclear, and FDG PET/CT is not currently recom-
mended for the diagnosis and staging of RCC based on updated 
national and international guidelines (42–44), it can effectively be 
used for postoperative surveillance and restaging as an adjunct 
when conventional imaging is not conclusive, as early diagnosis 
of recurrent/metastatic disease can drastically affect therapeutic 
decision and alter outcomes of patients (45). FDG uptake is help-
ful for differentiating benign or bland emboli from tumor throm-
bosis in RCC patients. FDG PET/CT has a higher sensitivity and 
accuracy in detecting bone metastases in patients with RCC than 
that of bone scan. Pretreatment SUVmax assessed by FDG PET/
CT can provide helpful information for clinical decision-making 
as it can serve as a useful prognostic marker for patients with 
advanced RCC. High SUVmax in patients with primary RCC is 
suggested with correlate with a high likelihood of metastasis, and 
FDG accumulation may be useful in estimating patient’s survival. 
In monitoring the efficacy of TKI treatment for advanced RCC, 
FDG PET/CT has been increasingly used to assess the therapeutic 
efficacy, and change of FDG uptake is a powerful index for evalu-
ating the biological response to TKI.
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